A devastating mass shooting at a Crown Heights hookah lounge has left three dead and nine injured. Witnesses describe the scene as a 'bloodbath' amid rising concerns about gang-related violence in NYC.
In a critical meeting in Washington, European leaders rally behind Ukraine's Zelenskiy as he navigates pressure from the U.S. for a swift peace deal with Russia, risking territorial concessions.
As Trump federalizes police in D.C., Mayor Muriel Bowser faces unprecedented challenges while balancing community concerns and federal intervention. Will she rise to the occasion?
OpenAI CEO Sam Altman reveals that while AI may eliminate some jobs, it will also create thrilling, high-paying opportunities, especially in space exploration. Discover why he believes the next decade is the best time to start your career!
Explore the intense dynamics in 'The Gilded Age' Season 3 finale as Bertha navigates relationships with her family and society. Will she emerge as the undeniable queen of high society?
Jamnagar, once in the spotlight for a celebrity wedding, is now at the center of a geopolitical crisis as U.S. tariffs on Indian oil test the limits of U.S.-India relations. The region's key refineries, led by Mukesh Ambani's Reliance Industries, face scrutiny amid rising tensions over Russian oil imports.
A gunman is dead following a shooting incident in Midtown Manhattan, injuring an NYPD officer and two civilians. The scene remains active as law enforcement investigates the unfolding situation.
In a startling earnings call, Elon Musk warns investors of a challenging transition for Tesla, citing revenue declines and shifting regulations. As the company navigates through these turbulent times, Musk hints at potential recovery by next year. Learn about the key takeaways and what the future holds for Tesla!
A gunman remains at large after shooting a driver who crashed into a crowd outside a popular East Hollywood club, injuring dozens. Eyewitnesses describe the chaotic scene as LAPD investigates.
In a stunning move, the FDA has put clinical trials for Sarepta's gene therapy on hold due to alarming safety concerns after multiple patient deaths linked to acute liver failure. The company faces scrutiny as it navigates the fallout.
